Tumor-associated antigen-presenting pathway via major histocompatibility complex class I and II molecules on autologous dendritic cells (null)

This entry describes not a single molecular target but rather an immunological process central to many cancer immunotherapies. The "tumor-associated antigen-presenting pathway via major histocompatibility complex (MHC) class I and II molecules on autologous dendritic cells" refers to the mechanism whereby a patient's own (autologous) dendritic cells are loaded with specific antigens derived from their tumor. These professional antigen-presenting cells then display processed peptides from these antigens on their surface using both MHC class I and II complexes. Presentation through MHC class I enables activation of CD8+ cytotoxic T lymphocytes, which can recognize and kill tumor cells displaying the same peptide-MHC complexes. Presentation through MHC class II activates CD4+ helper T-cells that support the overall immune response. This dual-presentation is critical for effective anti-tumor immunity. The approach forms the basis for several personalized cancer vaccine strategies where ex vivo–generated autologous DCs are pulsed with patient-derived tumor antigens before being reintroduced into the patient as a therapeutic vaccine. Clinical studies have shown that this method can induce robust cellular immune responses—primarily TH1/TH17—and has led to durable complete regressions in some patients with advanced cancers such as melanoma, glioblastoma, ovarian cancer, hepatocellular carcinoma, and renal cell carcinoma[6][8]. Safety profiles are generally favorable but may include mild injection site reactions or rare hypersensitivity events. Because this entry describes an entire biological process rather than a discrete molecular entity like a receptor or enzyme, it should not be considered a canonical therapeutic "target" in structured databases—it is more accurately classified as an immunotherapeutic strategy or mechanism involving multiple targets within the immune system[1][2][3].

Other names

Dendritic cell antigen presentation pathwayMHC class I and II tumor antigen presentationAutologous dendritic cell vaccine mechanismCross-presentation of tumor antigens by dendritic cells

Presentation of patient-specific tumor antigens by autologous dendritic cells via MHC class I to CD8+ T-cells induces cytotoxic immune responses against tumor cells[1][2][3].